This English translation is provided for convenience only. In the event of any discrepancies between the English translation and the original Swedish version, the Swedish version shall prevail.

Press release 2026-11-24

THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, PUBLICATION OR DISTRIBUTION OF THE INFORMATION WOULD NOT COMPLY WITH APPLICABLE RULES OR WOULD REQUIRE REGISTRATION OR ANY OTHER ACTION. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO ACQUIRE SECURITIES IN ACUCORT AB (PUBL). SEE ALSO THE SECTION "IMPORTANT INFORMATION" BELOW.

AcuCort AB: Last day for subscription in AcuCort's rights issue of units is 26 November 2026

Thursday, 26 November 2026, is the last day for subscription in AcuCort AB's ("AcuCort" or the "Company") rights issue of units (the "Rights Issue"). Please note that banks and nominees may set an earlier deadline for subscription. The issue volume initially amounts to a maximum of approximately SEK 70.3 million and is covered by subscription commitments and an underwriting commitment totaling approximately SEK 52.8 million, corresponding to approximately 75 percent of the Rights Issue. The proceeds from the Rights Issue are intended to finance the Company's continued work towards FDA approval for Zeqmelit® and thereby accelerate commercialization, while the capital is to support continued growth in existing markets, expansion in the US and enable establishment in selected international markets.

Summary of the Rights Issue

- Existing shareholders have received one (1) unit right per share held on the record date, which was 10 November 2026. Three (3) unit rights entitle the holder to subscribe for one (1) unit. One (1) unit contains three (3) shares and two (2) TO 3 warrants.
- Upon full subscription in the Rights Issue, AcuCort will initially receive approximately SEK 70.3 million before deduction of issue costs.
- The subscription price is SEK 0.90 per unit, corresponding to SEK 0.30 per share. TO 3 warrants are issued free of charge.
- The subscription period in the Rights Issue runs up to and including 26 November 2026.
- One (1) TO 3 warrant entitles the holder to subscribe for one (1) new share in the Company. The exercise period of ten (10) trading days is event-driven and based on receipt of FDA approval for Zeqmelit®, and may commence no earlier than 30 December 2026 and no later than 1 March 2028. Upon full exercise of TO 3 at the highest possible

subscription price, the Company may receive approximately SEK 93.8 million before deduction of issue costs.

- In total, the Rights Issue is covered by subscription commitments and an underwriting commitment of up to approximately 75 percent of the issue volume (corresponding to a total of approximately SEK 52.8 million).

Prospectus and teaser

For further information about the Rights Issue and the full terms and conditions, please refer to the prospectus relating to the Rights Issue (the "Prospectus"), which was approved by the Swedish Financial Supervisory Authority (Sw: Finansinspektionen) on 10 November 2026 and is available on AcuCort's website, www.acucort.se. The Prospectus is also available in the Swedish Financial Supervisory Authority's prospectus register (www.fi.se). The teaser is available on AcuCort's website.

Advisors

Navia Corporate Finance AB (www.naviacorporatefinance.com) is financial advisor and Sole Bookrunner in connection with the Rights Issue. HWF Advokater AB is the legal advisor. Vator Securities AB is the issuing agent.

For more information about the Rights Issue, please contact:

Navia Corporate Finance AB
Phone: 0046 10-148 76 80
E-mail: info@naviacf.se
Website: www.naviacorporatefinance.com

For more information about the Company, please contact:

Jonas Jönmark, CEO
Phone: 0046 70 365 54 00
E-mail: jonas.jonmark@acucort.com
Website: www.acucort.se

About AcuCort AB (publ)

AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a new, innovative, patented and user-friendly administration form, primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway and Finland, where the product is also marketed. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.

About Navia Corporate Finance AB

Navia Corporate Finance AB is a partner-owned corporate finance boutique providing high-quality advisory services and tailored financing solutions to listed and unlisted growth companies across Scandinavia. With more than 40 years of combined experience and over 300 completed transactions, Navia combines deep capital markets expertise with a close and entrepreneurial approach. The company advises clients on, among other things, capital raisings, stock market listings, financing solutions, investor relations and financial communications – from strategy and analysis through execution and follow-up. Navia is headquartered in Helsingborg.

Important information

The publication, announcement or distribution of this press release may be subject to restrictions in certain jurisdictions. Recipients of this press release in jurisdictions where this press release has been published or distributed are required to inform themselves of and comply with such restrictions. This press release does not constitute an offer to the public to acquire, subscribe for or otherwise trade in shares or other securities in the Company in any jurisdiction other than Sweden.

This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. An EU Follow-on Prospectus relating to the Rights Issue referred to in this press release has been prepared by the Company, approved by the Swedish Financial Supervisory Authority and published before the start of the subscription period. This press release contains information regarding the Rights Issue and constitutes an advertisement for the purposes of the Prospectus Regulation. Any investment decision should, in order for an investor to fully understand the potential risks and benefits associated with the decision to participate in the Rights Issue, only be made on the basis of the information contained in the Prospectus. Accordingly, an investor is advised to read the entire Prospectus.

Within the European Economic Area ("EEA"), no offer to the public of shares is made in any member state other than Sweden. In each other EEA member state, this communication is directed solely at "qualified investors" in that member state within the meaning of the Prospectus Regulation.

The information contained in this press release may not be announced, published or distributed, directly or indirectly, in or into the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, South Korea, Russia, Belarus or any other jurisdiction where the announcement, publication or distribution of the information would not comply with applicable laws and regulations or would require additional prospectuses, registration or other measures in addition to those required under Swedish law. The information contained in this press release may not be forwarded or reproduced in any manner that would contravene such restrictions or result in such requirements. Actions taken in violation of this instruction may constitute a breach of applicable securities laws. Neither unit rights, paid and subscribed units, new shares nor warrants subscribed for in the offering have been or will be registered under the United States Securities Act of 1933, as amended (the "Securities Act"), and may not be offered, subscribed for, exercised, pledged, sold, resold, delivered or transferred, directly or indirectly, in or into the United States, except pursuant to an applicable exemption from the registration requirements under the Securities Act.

In the United Kingdom, this press release is directed and communicated only to persons who are "qualified investors" (as defined in paragraph 15 of Schedule 1 to the Public Offers and Admissions to Trading Regulations 2024) and who: (i) have professional experience in matters relating to investments and fall within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), (ii) are high net worth entities falling within Article 49(2)(a)–(d) of the Order, or (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of Section 21 of the Financial Services and Markets Act 2000) may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "Relevant Persons"). Persons in the United Kingdom who are not Relevant Persons should not act or rely on the information contained in this press release or use it as a basis for taking any action. In the United Kingdom, any investment or investment activity to which this press release relates is available only to, and will be engaged in only with, Relevant Persons.

The Company assesses that it conducts activities that are subject to protection under the Swedish Screening of Foreign Direct Investments Act (2023:560) (the "FDI Act"). In accordance with the FDI Act, the Company must inform prospective investors that the Company's activities may fall within the scope of the legislation and that the investment may be subject to a notification requirement. If an investment is subject to a notification requirement, it must, prior to being made, be notified to the Inspectorate of Strategic Products (ISP). An investment may be subject to a notification requirement if, following completion of the investment, the investor, anyone within the investor's ownership structure or anyone on whose behalf the investor is acting, holds voting rights corresponding to or exceeding any of the thresholds of 10, 20, 30, 50, 65 or 90 percent of the total number of votes in the Company. The investor may be subject to an administrative penalty if an investment subject to a notification requirement is completed before the ISP has either: (i) decided to leave the notification without action, or (ii) approved the investment. Each investor should consult an independent legal adviser regarding the potential applicability of the FDI Act to the Rights Issue in respect of such individual investor.

Forward-looking statements

This press release contains forward-looking statements that reflect the Company's intentions, beliefs or current expectations regarding and targets for the Company's future operations, financial condition, liquidity, performance, prospects, expected growth, strategies and opportunities, as well as the markets in which the Company operates, including with respect to the prospects for pharmaceutical treatments and studies. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will", "should", "could", "aim" or "might" or, in each case, their negative or similar expressions. The forward-looking statements contained in this press release are based on various assumptions, many of which are in turn based on further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, no assurance can be given that they will occur or prove to be correct. As these statements are based on assumptions or estimates and are subject to risks and uncertainties, actual results or outcomes may differ materially from those expressed in the forward-looking statements as a result of numerous factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this press release through such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from error and accepts no responsibility for the future accuracy of the opinions expressed in this press release or any obligation to update or revise the statements contained herein to reflect subsequent events. The information, opinions and forward-looking statements contained in this press release speak only as of the date hereof and are subject to change without notice. The Company undertakes no obligation to review, update, confirm or publish any revisions to forward-looking statements to reflect events or circumstances arising in relation to the contents of this press release.